skip to main content
Close Icon We use cookies to improve your website experience.  To learn about our use of cookies and how you can manage your cookie settings, please see our Cookie Policy.  By continuing to use the website, you consent to our use of cookies.
Global Search Configuration

In-depth pharmaceutical market coverage

Datamonitor Healthcare | Pharma Intelligence

Discover unmet pharmaceutical needs. Effectively prioritize market opportunities. Deliver optimal returns. Datamonitor Healthcare’s in-depth expert data analysis and robust interactive data tools meet your needs and address your challenges in an ever-changing market.

How it helps

The breadth of coverage ensures you can assess revenue potential and identify competitive threats, market catalysts, and untapped new product development opportunities more holistically than ever before.

How it works

Content created by a global team of award-winning specialist analysts, and an easy-to-use interface that streamlines information gathering make Datamonitor Healthcare the go-to solution for the pharmaceutical and biotechnology industries.  

It offers:

  • Forecasts, built by our analysts, including patient-based, epidemiology, and sales forecasts
  • A myriad of interactive data tools, including treatment, standards of care by country, and patient-based disease forecasts, supported by large-scale primary research with physicians, payers, and key opinion leaders
  • Expert coverage and in-depth analysis of key diseases, companies, drugs and market trends

What's included

Pharma Intelligence: latest

  • Datamonitor Healthcare

    Gene Therapy: A Paradigm Shift in Medicine

    By Amanda Micklus 30 Nov 2018

    The following analysis reviews several aspects of the gene therapy market. The history of gene therapy is briefly discussed, alongside a look at the trend in the volume of candidates in development over the past 20+ years, and how the regulatory landscape in the US and EU has recently adapted to help move the field forward. A deep dive into the pipeline with  breakdowns by delivery method and therapy area is provided, as are the key companies involved and the major partnership deals that have made gene therapy a hot commodity. Manufacturing, pricing, and reimbursement issues are also addressed.

    Topic Cell and gene therapy

  • Biomedtracker, Datamonitor Healthcare

    December 2018 National Influenza Week

    29 Nov 2018

    3 – 9 December is National Influenza Vaccination Week, a national awareness week focused on highlighting the importance of influenza vaccination. In this free KOL Insight Interview excerpt from Datamonitor Healthcare, read what key opinion leaders from the UK and US in Infectious Diseases have to say about current efforts to combat influenza with seasonal influenza vaccines:

    Topic Influenza virus Infectious diseases

  • Datamonitor Healthcare

    World AIDS Day 2018 GlaxoSmithKline report

    29 Nov 2018

    PharmaVitae explores GlaxoSmithKline’s prescription pharmaceutical performance and outlook over 2017–27. PharmaVitae analyses include quarterly earnings coverage and provide timely updates to company product forecasts. The full company profile encompasses analysis on corporate strategy, portfolio analysis, pipeline potential, and financial performance.

    Topic Diseases Drug development landscape Drug review

  • Datamonitor Healthcare

    Depression Disease Market and Forecast Analysis 2024

    24 Oct 2018

    Informa Pharma Intelligence is marking Depression Awareness Month with a free download of Depression Disease Market and Forecast Analysis 2024. Download your free extract from this vital report and tap into the exclusive data and insights into the depression market available only from the experts at Datamonitor Healthcare, part of the Informa Pharma Intelligence suite of tools.

    Topic Drug development landscape

  • Datamonitor Healthcare

    Better Heart Health Whitepaper

    22 Oct 2018

    In recognition of World Heart Day, September 29, 2018, Informa Pharma Intelligence would like to invite you to download our latest whitepaper, Better Heart Health with Mobile Apps? The Impact of Mobile Apps on Coronary Heart Disease in the US. This exploration into the results of a recent analysis of the US Behavioral Risk Factor Surveillance System (BRFSS), coupled with an analysis of several health apps targeting coronary heart disease (CHD) and other heart disease factors, is available to you now – for free.

  • Datamonitor Healthcare

    Neuropathic Pain Market and Forecast Analysis to 2026

    By Nicola Sawalhi-Leckenby 07 Sep 2018

    Big changes are coming to the neuropathic pain market – are you prepared? Take a look at the projected neuropathic pain drug sales for the US, Japan, and five EU nations with the latest infographic from Datamonitor Healthcare. This snapshot view of the future of the neuropathic pain market is packed with data from the full Datamonitor Healthcare Neuropathic Pain Disease Coverage report.

  • Datamonitor Healthcare

    Meningococcal Vaccines Forecast Infographic

    By Karolina Kujawa 28 Aug 2018

    Over 1.2 million cases of bacterial meningitis are estimated to occur worldwide each year. If not treated promptly, up to half of those cases will be fatal. This infographic from Datamonitor Healthcare provides a snapshot of the meningococcal vaccines market in the US and five major EU markets. What does the meningococcal vaccines market have in store and how will it affect your business? Download now.

    Topic Vaccines

  • Datamonitor Healthcare

    Epidiolex and Epilepsy - big changes for medical marijuana

    By Stephanie Yip 28 Aug 2018

    With the FDA’s landmark approval of Epidiolex, a cannabidiol used to treat rare, severe pediatric epilepsies, the only obstacle to the legal sale of the drug is DEA reclassification of cannabidiol (CBD). With reclassification likely in the next 90 days, what does it mean for the epilepsy market, as well as the wider market for CBD?

    Topic Drug approval

  • Datamonitor Healthcare

    Japan Pharma Outlook 2027 Report Extract

    27 Aug 2018

    Download your complimentary Japan Pharma Outlook 2027 report extract. The 16-page excerpt includes highlights from the full report, which is available to subscribers of Datamonitor Healthcare, and available to purchase on our Report Store. Discover now the complex challenges and opportunities facing Japan Pharma.

  • Datamonitor Healthcare

    Trends in Gene Therapy Seminar

    By Patricia Reilly 22 Aug 2018

    The promises of gene therapy are taking a long time to be fulfilled, in part due to challenges in developing gene vectors capable of safe and efficient delivery of therapeutic genes (transgenes) into patients’ cells. Nonetheless, these challenges are being addressed in innovative ways. A variety of first-generation vectors, both viral and non-viral, have been employed in clinical trials with varying degrees of success, and the experience gained is guiding the design of next-generation vectors.

  • Datamonitor Healthcare

    Podcast - Analyst Opinion on Approval of AndexXa for reversal of Eliquis and Xarelto

    By Zachary McLellan 22 Aug 2018

    Zach McLellan, Jack Allen, and guest analyst Cameron Findlater discuss current events in the healthcare space in the Datamonitor Healthcare Analyst Podcast, including the approval of AndexXa for reversal of Eliquis and Xarelto & Eli Lilly's acquisition of ARMO Biosciences.

  • Datamonitor Healthcare

    Japan Pharma Outlook Webinar Recording

    By Ian Haydock 22 Aug 2018

    Listen to this insightful presentation of the unique challenges and opportunities faced by Japan Pharma, hosted by the expert analysts from Pharma Intelligence.

    Topic Drug development landscape

  • Datamonitor Healthcare

    Datamonitor Healthcare Analyst Podcast: Post-ASCO Podcast 2

    By Jack Allen 22 Aug 2018

    Zach McLellan and Jack Allen are joined by guest analyst Maria Berezina. The group discusses key recent events that occurred at the American Society of Clinical Oncology 2018 Annual Meeting.

    Topic Cancer

  • Datamonitor Healthcare

    Datamonitor Healthcare Analyst Podcast: Post-ASCO Podcast 1

    By Jack Allen 22 Aug 2018

    Zach McLellan and Jack Allen are joined by guest analysts Dominique Fontanilla and Hardik Patel. The group discusses key recent events that occurred at the American Society of Clinical Oncology 2018 Annual Meeting.

    Topic Cancer

  • Datamonitor Healthcare

    Business Development and Licensing Video

    01 Jul 2018

    If you’re a senior business development and licensing professional in pharma or biotech, it’s your job to ensure that your company’s revenue pipeline is full of viable opportunities and accelerate growth for your organisation. Watch this short video  and discover how Informa’s Pharma Intelligence provides the rock-solid intelligence you need to accelerate growth and drive business forward.

    Topic Business strategies

Meet the team

Analyst

Rachel Meighan-Mantha

Analyst, Principal Analyst
Rachel Meighan-Mantha

Rachel specializes in

  • Oncology
  • Clinical Trials

+22 year(s) experience

Analyst

Amanda Micklus

Analyst, Principal Analyst

Connecticut

Amanda Micklus

Amanda specializes in

  • Oncology
  • Business Development & Licensing
  • Commercial Strategy

+18 year(s) experience

Management

Michael Hay

Management, Head of Intelligence Products
Michael Hay

Michael specializes in

  • Business Development & Licensing
  • Commercial Strategy

+18 year(s) experience

Keep up to date

Next steps

Getting a demo tailored to your needs is the best way to see how our solutions will help you gain an advantage.

Request live demo now:

Our team is always happy to hear from you. Please call us at:

  • US Toll-Free  : +1 888 670 8900
  • US Toll           : +1 908 547 2200
  • UK & Europe : +44 (20) 337 73737
  • Australia        : +61 2 8705 6907
  • Japan              : +81 3 6273 4260

Or please submit your inquiry via the form so that we can provide you the best possible customer service.

Have an immediate and specific information need?

Browse and buy from 1000s of analysis and research reports now: